Bimode is a chemotherapy medication used in the treatment of certain cancers, including chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL). It belongs to the class of drugs known as alkylating agents and is available as an injection for intravenous use. Bimode works by damaging the DNA of cancer cells, which prevents them from dividing and leads to their destruction. This dual-action mechanism-alkylation and disruption of DNA repair pathways-makes it effective in targeting rapidly growing cancer cells.

Indications:

• Chronic Lymphocytic Leukemia (CLL)
• Indolent Non-Hodgkin's Lymphoma (iNHL) that has not responded to other treatments
• Off-label uses as determined by oncologists

Common side effects: Nausea, vomiting, and diarrhea, Fatigue and weakness, Low blood cell counts (anemia, neutropenia, thrombocytopenia), Fever or increased susceptibility to infections, Skin reactions, such as rash.

Precautions

• Monitoring: Regular blood tests are required to monitor blood counts and organ function.
• Pregnancy and Breastfeeding: Bimode is not recommended during pregnancy or breastfeeding due to potential harm to the fetus or infant.
• Drug Interactions: Inform your doctor about any medications, supplements, or herbal products you are taking to avoid interactions.
• Renal or Liver Impairment: Dose adjustments may be necessary for patients with kidney or liver issues.

Storage

• Store Bimode vials at 20–25°C (68–77°F).
• Reconstituted solutions should be used promptly or stored under recommended conditions per the manufacturer’s guidelines.

• Route of Administration: Intravenous infusion.
• Dosage: The typical dose for CLL is 100 mg/m² on Days 1 and 2 of a 28-day cycle. For NHL, the dose is usually 120 mg/m² on Days 1 and 2 of a 21-day cycle.
• The dosage and number of cycles depend on the patient’s condition, response to therapy, and overall health.